Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 3/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16209719 | 0.89 | AKT2 (0.79) | AKT2CHEK1KMT2AMKNK1CHUK | |
| SCHEMBL21262737 | 0.83 | AKT2 (0.70) | AKT2CHEK1KMT2AMKNK1CHUK | |
| SCHEMBL12559254 | 0.81 | AKT2 (0.67) | AKT2CHEK1KMT2AMKNK1FTO | |
| SCHEMBL5865715 | 0.81 | AKT2 (0.68) | AKT2CHEK1KMT2AL3MBTL1BRD4 | |
| SCHEMBL11192094 | 0.81 | AKT2 (0.68) | AKT2CHEK1KMT2AL3MBTL1GRM5 | |
| SCHEMBL28979838 | 0.81 | AKT2 (0.68) | AKT2CHEK1KMT2AMKNK1CHUK | |
| SCHEMBL13035810 | 0.80 | AKT2 (0.67) | AKT2CHEK1KMT2AIKBKBIKBKE | |
| SCHEMBL23091872 | 0.79 | IKBKB (0.68) | AKT2CHEK1KMT2AMKNK1L3MBTL1 | |
| SCHEMBL11116234 | 0.79 | AKT2 (0.66) | AKT2CHEK1KMT2AL3MBTL1CHUK | |
| SCHEMBL2374203 | 0.79 | AKT2 (0.66) | AKT2CHEK1KMT2AL3MBTL1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619233-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2013-07-31 | — | — | EP | claimed |
| CN-103154044-A | Process for producing polydienes | BRIDGESTONE CORP | 2013-06-12 | — | — | CN | claimed |
| WO-2012040026-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | WO | claimed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023114200-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-109608506-B | Quadrivalent metal platinum complex containing tetradentate ligand, preparation method, application and device | 浙江工业大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-108299507-B | Tetradentate ring metal platinum complex containing trisubstituted pyrazole, preparation method and application | 瑞声光电科技(常州)有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20190337973-A1 | TETRADENTATE CYCLOMETALATED PLATINUM COMPLEX COMPRISING TRISUBSTITUTED PYRAZOLE, PREPARATION AND USE THEREOF | AAC MICROTECH(CHANGZHOU)CO.,LTD. (CN) | 2019-11-07 | — | — | US | disclosed |
| US-20190322928-A1 | TETRADENTATE CYCLIC-METAL PLATINUM COMPLEXES COMPRISING 6-SUBSTITUTED CARBAZOLE, PRERATION AND USE THEREOF | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2019-10-24 | — | — | US | disclosed |
| US-20190233454-A1 | Tetradentate ring metal platinum complex containing trisubstituted pyrazole and preparation method and application | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20050119246-A1 | 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-02 | — | — | US | disclosed |
| EP-1495005-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1465871-A1 | PYRAZOLE DERIVATIVES FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | Bayer Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003057673-A1 | 1H-PYRAZOLYL DERIVATIVE COMPOUNDS, FOR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-0087780-A2 | Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1983-09-07 | — | — | EP | disclosed |
| US-4359398-A | Liquid crystal compositions with novel tris-azo dichroic dyes | GENERAL ELECTRIC COMPANY (US) | 1982-11-16 | — | — | US | disclosed |
| US-4072498-A | HERBICIDES | THE UPJOHN COMPANY (US) | 1978-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233454-A1 | Tetradentate ring metal platinum complex containing trisubstituted pyrazole and preparation method and application | PTCD3, TRPC3, EXOC3 | AKT2 3744/4885CHEK1 742/4885KMT2A 3119/4885 |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | AKT2 4473/4885CHEK1 4860/4885KMT2A 2815/4885 |
| US-20050119246-A1 | 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction | HTR2C, GPR119, HTR2B | AKT2 2613/4885CHEK1 3222/4885KMT2A 305/4885 |
| US-20190337973-A1 | TETRADENTATE CYCLOMETALATED PLATINUM COMPLEX COMPRISING TRISUBSTITUTED PYRAZOLE, PREPARATION AND USE THEREOF | PDCD4, PDCD5, PDCD1 | AKT2 2848/4885CHEK1 303/4885KMT2A 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.